Quoted Micro 10 August 2026
AQUIS STOCK EXCHANGE Heart health products developer ProBiotix Health (PBX) interim revenues increased 53% to £2.06m and improved gross margins. There was a swing from a loss of £153,000 to a pre-tax profit of £79,000. The growth was in the US. There was a £19,000 cash outflow from operating activities during the period and £1.24m […]
Quoted Micro 27 July 2026
AQUIS STOCK EXCHANGE Arbuthnot Banking (ARBB) had a good first half performance and expectations have been upgraded. Interim pre-tax profit was flat and financial headroom remains comfortable. Improved efficiency helped to maintain profit when interest rates were lower. Specialist lending grew 18%. There is growth in the core businesses, but higher technology costs offset this […]
Quoted Micro 8 June 2026
AQUIS STOCK EXCHANGE Incanthera (INC) is acquiring skincare brand Enielle for up to 54 million shares at 2p each depending on performance and its owner and boss Stuart Robertson will become Incanthera chief executive, taking over from Dr Simon Ward who will remain on the board. Tim McCarthy is stepping down as executive chairman. Enielle […]
Quoted Micro 1 June 2026
AQUIS STOCK EXCHANGE ProBiotix Health (PBX) has secured a new strategic alliance with Spain-based Bioksan, covering Spain and Portugal. ProBiotix will supply the LPLDL® probiotic strain to Bioksan to replace red yeast rice, which has a compound that might be prohibited in the EU. This deal is worth €200,000. There could be other companies that require […]
Quoted Micro 6 April 2026
AQUIS STOCK EXCHANGE In 2025, heart health products developer ProBiotix Health (PBX) increased revenues by 45% to £2.73m. The loss was reduced from £852,000 to £1.24m. Revenues continue to grow in the first quarter of the new financial year, and it has achieved profitability. Cash was £1.27m at the end of 2025. The order book […]
Quoted Micro 23 February 2026
AQUIS STOCK EXCHANGE Cooks Coffee Company (COOK) says its UK Esquires coffee stores generated revenues of £21.9m in the nine months to December 2025, while sales in Ireland were 27% higher at £9.9m. There was like-for-like growth of 5.1% and 6.3% respectively. Income comes predominantly from franchise fees and royalties. Delta Gold Technologies (DGQ), the […]
Quoted Micro 9 February 2026
AQUIS STOCK EXCHANGE Sulnox Group (SNOX) has generated £1.69m in the nine months to December 2025, compared with £650,000 in the comparative period. A further £335,000 of sales have been generated since then. So far this year, emissions reduction additive volumes grew 265%. Cash was £1.12m at the end of 2025. Delta Gold Technologies (DQG) […]
Quoted Micro 26 January 2026
AQUIS STOCK EXCHANGE Cardiometabolic health products developer ProBiotix Health (PBX) increased sales by 45% to £2.72m in 2025 and reduced the loss. During the year, ProBiotix entered the Korean market and submitted applications for two new clinical trials. There was £1.27m in the bank at the end of £1.27m. The order book is worth £1.3m. […]
Quoted Micro 10 November 2025
AQUIS STOCK EXCHANGE Asset and fund managers advisory services provider Falconedge (EDGE) joined Aquis on 5 November. The company was formed in 2024, and it has five clients. There was £1.44m raised at 1.034p/share. It previously raised £1m. Falconedge was valued at £10.5m on admission. Falconedge has already bought 15.16258228 Bitcoin at $103,553.97 each. The […]
Quoted Micro 20 October 2025
AQUIS STOCK EXCHANGE ProBiotix Health (PBX) increased sales 30% to £1.97m in the nine months to September 2025. There is sufficient cash for the company’s needs. A commercial partnership with RevivaBio has been set up to launch a new cholesterol lowering product powered by the ProBiotix patented probiotic strain LPLDL®. Chairman Adam Rynolds bought 100,000 […]